Targacept is a clinical-stage biopharmaceutical company engaged in developing a varied pipeline of innovative NNR therapeutics for hard-to-treat nervous system diseases and disorders. The company’s clinical pipeline includes multiple Phase 2 product candidates that all represent first-in-class opportunities, and Targacept … Continue reading →

  Provectus Pharmaceuticals is a biopharmaceutical company specializing in the development of oncology and dermatology therapies. PV-10, the company’s novel oncology drug, is designed to selectively target and destroy cancer cells without harming the surrounding healthy tissue. Provectus has received … Continue reading →

NovaBay Pharmaceuticals is a biotechnology company engaged in using its two distinct categories of product offerings – Aganocides and NeutroPhase Skin and Wound Cleanser – to address the large, unmet therapeutic needs of the worldwide anti-infective market. The company has … Continue reading →

Agenus is a biotechnology company engaged in developing treatments for cancers and infectious diseases. The company’s focus is on immunotherapeutic products based on strong platform technologies, with multiple product candidates advancing through the clinic, including a number of product candidates … Continue reading →

Tonix Pharmaceuticals Holding is focused on the development of innovative prescription medicines for challenging disorders of the central nervous system. Tonix targets conditions characterized by significant unmet medical need, inadequate existing treatments and high patient and physician dissatisfaction. The company’s … Continue reading →

Palatin Technologies is a biopharmaceutical company engaged in the development of targeted, receptor-specific peptide therapeutics for treating diseases that have significant unmet medical need but where there is also commercial potential. The company’s strategy involves developing products and then forming … Continue reading →

Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery of breakthrough treatments for human disease. Currently, the company has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis. The company has identified … Continue reading →

CEL-SCI is a biotechnology company engaged in research and development directed toward improving treatments for cancer and other diseases through utilization of the immune system – the body’s natural defense system. Multikine, the company’s lead investigational therapy, is being studied … Continue reading →

Repros Therapeutics is a development-stage biopharmaceutical company focused on developing oral small molecule drugs to address major unmet medical needs for male and female reproductive disorders. The company’s primary product candidate is Androxal, an orally active proprietary small molecule compound … Continue reading →

GENFIT is a biopharmaceutical company at the forefront of drug discovery and development. The company’s focus is on the early diagnosis and preventive treatment of cardiometabolic and associated disorders. GENFIT’s mission is bringing therapeutic and diagnostic solutions to the pharmaceutical … Continue reading →